There have been few opportunities for value investors to purchase CSL shares, with the stock trading primarily above value in recent years

Amelia Bott
StocksInValue
There have been few opportunities for value investors to purchase CSL shares, with the stock trading primarily above value in recent years. CSL is returning to value and has a positive outlook underpinned by an ageing population, increasing health care expenditure in emerging markets and greater recognition of the benefits of its therapies. The successful commercialisation of its research and development pipeline would provide further upside to earnings. For the full article published in Eureka Report (VIEW LINK)
Never miss an update
Enjoy this wire? Hit the ‘like’ button to let us know.
Stay up to date with my current content by
following me below and you’ll be notified every time I post a wire
Welcome to Livewire, Australia’s most trusted source of investment insights and analysis.
To continue reading this wire and get unlimited access to Livewire, join for free now and become a more informed and confident investor.
Already have an account? Sign in here

Never miss an update
Get the latest insights from me in your inbox when they’re published.
2 topics

Amelia Bott
Equities Analyst
StocksInValue
Expertise
No areas of expertise
Comments
Comments
most popular
Macro
Why Silicon Valley Bank Died (UPDATED 2)...
Coolabah Capital
Macro
The Risk of Higher Rates the RBA’s Overlooking
Leithner & Company Ltd
Please sign in to comment on this wire.